Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release. Questions? Email: firstname.lastname@example.org
Exact Sciences makes understanding Oncotype DX Colon Recurrence Score® test results as easy as possible.
Understanding Colon Recurrence Score® reports
There are 2 reports tailored to the patient’s anatomic stage: stage II MMR-P or stage III A/B.
Anatomic stage II MMR-P report
The anatomic stage II MMR-P report consists of 2 pages that include the following information:
Page 1 summarizes the risk of recurrence following surgery alone. You’ll see the Recurrence Score® result, along with the associated recurrence risk estimate following surgery for MMR-P patients by T stage. For patients whose Recurrence Score result is ≥41, shading in the graph indicates a higher risk
Page 2 shows the risk of recurrence following chemotherapy. You’ll see the patient’s Recurrence Score result, now with the associated recurrence risk estimate following 5-FU/LV alone or in combination with oxaliplatin. For patients whose Recurrence Score result is ≥41, shading in the graph indicates a higher risk